Research field (2)：
Neuroscience - general
, Psychiatry
Research keywords (11)：
treatment guideline
, geriatric depression
, DNA methylation
, gene expression
, psychopharmacology
, bipolar disorder
, schizophrenia
, Alzheimer's disease
, biomarker
, dementia with Lewy bodies
, major depressive disorder
Research theme for competitive and other funds (7)：
2022 - 2025 Research on neuropsychiatric disorders in the elderly focusing on the cellular senescence
2018 - 2020 Blood biomarker for differentiating geriatric depression from Alzheimer's disease
2015 - 2017 Early life adversity and 5HTT mRNA expression and DNA methylation in patients with major depressive disorder
2011 - 2012 Biological diagnostic test for major depressive disorder based on the leukocytes gene expression
2006 - 2007 うつ病におけるLIM関連遺伝子群の分子医学的検討
うつ病の病態解明
pathophysiology of major depression
Show all
Papers (172)：
Hiroaki Mori, Shinichiro Ochi, Hidetoshi Hashida, Jun-ichi Iga, Shu-ichi Ueno. Efficacy of Guanfacine for Self-injurious and Aggressive Behaviors through the Reduction of Impulsivity in Borderline Personality Disorder: Two Case Reports and a Literature Review. Clinical Psychopharmacology and Neuroscience. 2025
Yuta Yoshino, Toru Yagi, Koichi Tsubouchi, Yusuke Takaishi, Yuki Ozaki, Jun-ichi Iga, Keiichi Matsubara, Yuko Matsubara, Yuka Uchikura, Takashi Sugiyama, et al. Effects of Psychotropic Medications Taken by Pregnant Women on Newborn Medical Condition and Lactation Method. Neuropsychopharmacology Reports. 2025
Hiroaki Mori, Yuta Yoshino, Mariko Okano, Yu Funahashi, Hiroshi Kumon, Shinichiro Ochi, Jun-Ichi Iga, Shu-Ichi Ueno. Association Between Stress-Induced Weight Loss and Autophagy-Related Gene Expression in the Hippocampus and Midbrain of Depression Model Mice. Neuropsychopharmacology reports. 2025. 45. 1. e12515
Shinichiro Ochi, Takashi Tsuboi, Naomi Hasegawa, Hikaru Hori, Kayo Ichihashi, Yayoi Imamura, Tsuyoshi Okada, Fumitoshi Kodaka, Yoshitaka Saito, Jun-ichi Iga, et al. The association between benzodiazepine prescriptions and the risk of laxative use in schizophrenia treatment. Neuropsychopharmacology Reports. 2025
*Shinichiro Ochi, Fumitoshi Kodaka, Naomi Hasegawa, Jun-Ichi Iga, Hiroko Kashiwagi, Hiroshi Komatsu, Hiromi Tagata, Takashi Tsuboi, Shusuke Numata, Hitoshi Iida, et al. ASSOCIATIONS OF CLOZAPINE AVAILABLE INSTITUTION AND THE DIAGNOSIS OF SUBGROUPS ABOUT TREATMENT-RESISTANT SCHIZOPHRENIA OR NOT WITH A HIGHER RATE OF ANTIPSYCHOTIC MONOTHERAPY AND LOWER OTHER CONCOMITANT PSYCHOTROPICS IN OVERALL SCHIZOPHRENIA TREATMENT: A REAL-WORLD NATIONWIDE STUDY. International Journal of Neuropsychopharmacology. 2025. 28. Supplement_1. i163-i164
越智紳一郎, 小高文聰, 長谷川尚美, 伊賀淳一, 柏木宏子, 小松浩, 田形弘実, 坪井貴嗣, 沼田周助, 飯田仁志, et al. Associations of clozapine available institution and the diagnosis of subgroups about treatment resistant schizophrenia with higher rate of antipsychotic monotherapy in overall schizophrenia treatment. 統合失調症研究(CD-ROM). 2024. 13. 1
